Spring in Gusu set the stage as the BIOCHINA 2026 (11th Edition) EBC Biotech Industry Conference and Exhibition opened on March 12 at the Suzhou International Expo Center. The event featured 900+ speakers across six specialized exhibition halls and welcomed nearly 30,000 industry professionals from more than 40 countries and regions—creating meaningful value across the biopharmaceutical supply chain.
Morimatsu and Bioengineering AG made their first joint appearance, drawing strong attention from attendees. A pioneer in bioreactor technology, Bioengineering AG is widely recognized for its deep technical expertise and continued innovation in global bioprocessing. The collaboration brings together complementary core technologies and global market strengths. Through integrated technical capabilities and value-driven strategies, the partnership connects critical stages from R&D to commercialization, building a more complete support system and delivering stronger, more sustainable momentum for the biopharmaceutical industry.
At this year’s exhibition, we presented more comprehensive and forward-looking solutions aligned with industry needs, earning positive feedback and strong recognition from professionals across the field.
01 Upstream Cultivation & Downstream Separation and Purification Solutions
Designed for a wide range of applications, our integrated solutions support drug development, regulatory approval, and commercial manufacturing with streamlined, reliable, and efficient workflows.
02 Single-Use Solutions
Morimatsu's single-use solution, with its advantages of speed, flexibility, and low cross-contamination risk, enables efficient and adaptable biopharmaceutical production.
03 Pharmadule Morimatsu's Integrated Plant Solutions
Morimatsu's modular plant offers a turnkey total solution from design to validation, saving time in constructing new plant buildings and significantly reducing on-site construction. This enables overall off-site relocation of the building, meeting pharmaceutical companies' needs for rapid product launches and flexible production expansion.
During the event, Mr. Gao Yang, General Manager of the Bioengineering Division at Morimatsu LifeSciences and Deputy General Manager of Shanghai Mori-Biounion Technology Co., Ltd., was interviewed by the event organizer, Enmore. He outlined Morimatsu’s core business and addressed the global expansion of China’s biopharmaceutical industry, highlighting the company’s active push into overseas markets and deeper collaboration with international partners to accelerate globalization. Discussing industry opportunities and challenges, he also shared Morimatsu’s strategy of leveraging technological innovation and premium services to navigate market cycles and pursue new growth alongside its clients.
On the first afternoon, at the Innovative Process Technology Development Forum, Mr. He Guolun, Deputy General Manager of Morimatsu Biotechnology, delivered a keynote titled “Bioreactor Scale-Up: Key Design Considerations from Pilot to Commercial Production”. Cell culture technology is inherently complex and operates across multiple scales. Moving from pilot runs to commercial production often introduces significant process risk, making first-pass scale-up success critical to avoiding costly setbacks. His presentation outlined the core principles of scale-up technology and shared practical implementation pathways and response strategies.
Morimatsu used this exhibition as a bridge to engage deeply with industry peers—sharing leading innovations while uncovering new opportunities through open dialogue. With a strong market focus, the company listens closely to customer needs, welcomes feedback, and continues to expand its global collaboration network.
Amid the rapid growth of the global biopharmaceutical industry, Morimatsu draws on deep process expertise and ongoing technological innovation to deliver high-quality products and dependable services that support industry transformation and advancement. The company is committed to working alongside global partners to drive progress in healthcare.
About Morimatsu LifeSciences
Morimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK). It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai Morisora Technology Co., Ltd., Bioengineering AG, Pharmadule Morimatsu AB, and its affiliated companies.
Morimatsu LifeSciences is dedicated in providing core equipment, process systems, and smart modular facility solutions, and services for the pharmaceutical, biopharmaceutical, medical aesthetics, and fast-moving consumer goods (FMCG) sectors including (cosmetics, food, and health supplements), as well as data centers.
Our team comprises highly experienced professionals with deep expertise in process R&D, engineering design, advanced manufacturing, compliance and validation consulting, production execution, and intelligent operations. With broad experience across diverse industries, we fully understand the unique characteristics and process requirements of various products. This enables us to deliver tailored, end-to-end process solutions from the conceptual design stage, precisely aligned with client’s specific needs.
Morimatsu LifeSciences has established a strong global presence, supported by advanced R&D centers, design hubs, and state-of-the-art manufacturing facilities worldwide. Our well-established service network spans Europe,USA,Asia-Pacific, and emerging markets. We have successfully delivered outstanding, customized solutions to clients in over 40 countries and regions, gaining extensive experience in international project execution.
As a multinational enterprise with core strengths in process technology, modular facility construction, and intelligent manufacturing, Morimatsu LifeSciences is dedicated to meeting the evolving equipment and system needs of our key industries. Through continuous innovation and technological advancement, we are steadily expanding our global footprint, driving our international strategy forward, and delivering Morimatsu’s expertise, reliability, and innovation to the global life sciences and related sectors.
